US · Healthcare · Diagnostics & Research
EPS came in at -0.30 against a street estimate of -0.25 — a miss of 20.0%.
Analysts rate Personalis Inc a hold (1 buy, 4 hold, 0 sell out of 5) with an average price target of $15.17.
| Fund | Stake |
|---|---|
| Merck & Co Inc | 13.15% |
| ARK Investment Management LLC | 7.74% |
| BlackRock Inc | 6.63% |
| Lightspeed Management Co LLC | 5.71% |
| Ameriprise Financial Inc | 5.70% |
| Deep Track Capital, LP | 3.75% |
| Aberdeen Group PLC | 3.51% |
| Vanguard Capital Management, LLC | 2.82% |
| Document | Date |
|---|---|
| Company announcement · Q4 2026 HEADLINE NUMBERS • Personalis filed an 8-K dated October 6, 2026, reporting developments in its proposed merger with Tempus AI. • The Hart-Scott-Rod | 2026-10-06 |
| Company announcement · Q3 2026 PERSONALIS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company received new task order from U.S. Department of Veterans Affairs (VA) for the Million Vete | 2026-08-20 |
| Quarterly report · Q2 2026 PERSONALIS, INC. – 10-Q SUMMARY FOR Q2 2026 HEADLINE NUMBERS • Revenue Q2 2026: $22.4 million (up 30% vs. Q2 2025's $17.2 million) • Revenue H1 2026 | 2026-08-04 |
| Results announced · Q3 2026 PERSONALIS Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Total Revenue: $22.4 million in Q2 2026, up 30% year-over-year from $17.2 million in Q2 2025 • | 2026-08-04 |
| Material agreement · Q3 2026 PERSONALIS, INC. – MERGER AGREEMENT SUMMARY HEADLINE NUMBERS • Merger consideration per share: $16.25 in cash OR stock in Tempus AI (exchange ratio | 2026-07-20 |
| Results announced · Q3 2026 TEMPUS ACQUISITION OF PERSONALIS – INVESTOR SUMMARY HEADLINE NUMBERS • Acquisition Price: $16.25 per share of Personalis common stock • Total Enterp | 2026-07-20 |
| Quarterly report · Q1 2026 PERSONALIS, INC. — Q1 2026 SUMMARY --- HEADLINE NUMBERS • Revenue Q1 2026: $15.5 million (down 25% vs Q1 2025: $20.6 million) • Net Loss Q1 2026: $ | 2026-05-07 |
| Proxy statement · Q2 2026 PERSONALIS, INC. — PROXY SUMMARY FOR RETAIL INVESTORS CEO COMPENSATION • Richard Chen, President and Chief Executive Officer: Total compensation $2, | 2026-04-02 |
Readable in the app.
| Announcement | Date |
|---|---|
| Personalis announced merger agreement with Tempus AI Personalis reported that the U.S. antitrust review waiting period for its planned acquisition by Tempus AI expired on October 2, 2026. Tempus had withdrawn and refiled its antitrust notifica | 2026-10-06 |
| New $18.3M task order received under VA Million Veteran Program contract Personalis, Inc. received a new task order from the U.S. Department of Veterans Affairs (VA) for its Million Veteran Program (VA MVP) worth up to $18.3 million, effective September 30, 2026. | 2026-08-20 |
| Secured Medicare coverage for NeXT Personal for IO monitoring and breast cancer Personalis, a precision oncology genomics company, reported strong Q2 2026 results with exceptional growth. Clinical test volume surged 199% year-over-year to 10,384 tests, while clinical re | 2026-08-04 |
| Proposed business combination transaction between Tempus and the Company This 8-K filing announces a proposed business combination (merger) between Tempus and another company. The document is primarily a legal disclosure containing forward-looking statements and | 2026-07-20 |
| Entered into Agreement and Plan of Merger with Tempus AI Personalis, Inc. announced it has agreed to be acquired by Tempus AI, Inc. in an all-stock or mixed stock-and-cash merger transaction. Under the deal, Personalis shareholders will receive sh | 2026-07-20 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Personalis Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.